Humanization of an anti-ICAM-1 antibody with over 50-fold affinity and functional improvement

J Immunol Methods. 2003 Apr 1;275(1-2):31-40. doi: 10.1016/s0022-1759(02)00542-2.

Abstract

The monoclonal antibody 1A6 binds to human intercellular adhesion molecule 1 (ICAM-1, CD54) and inhibits infection by 90% of human rhinovirus (HRV) serotypes. To make a therapeutic molecule for preventing and treating HRV infection, we humanized a single chain antibody (scFv), 1A6, by a structure-guided complementarity-determining region (CDR) grafting procedure. Our final humanized 1A6 scFv does not retain any mouse back mutations in the framework. Without changing the CDR sequences, the humanized 1A6 scFv demonstrates over 50-fold improvement in both affinity for ICAM-1 and protection efficacy against HRV infection in vitro.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Amino Acid Sequence
  • Animals
  • Antibodies, Monoclonal / chemistry
  • Antibodies, Monoclonal / genetics*
  • Antibodies, Monoclonal / immunology*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Viral / chemistry
  • Antibodies, Viral / genetics
  • Antibodies, Viral / immunology
  • Antibodies, Viral / therapeutic use
  • Antibody Affinity
  • Complementarity Determining Regions
  • Humans
  • Intercellular Adhesion Molecule-1 / immunology*
  • Mice
  • Models, Molecular
  • Molecular Sequence Data
  • Picornaviridae Infections / prevention & control
  • Picornaviridae Infections / therapy
  • Picornaviridae Infections / virology
  • Protein Engineering
  • Recombinant Fusion Proteins / chemistry
  • Recombinant Fusion Proteins / genetics
  • Recombinant Fusion Proteins / immunology
  • Recombinant Fusion Proteins / therapeutic use
  • Rhinovirus / immunology*
  • Sequence Homology, Amino Acid

Substances

  • Antibodies, Monoclonal
  • Antibodies, Viral
  • Complementarity Determining Regions
  • Recombinant Fusion Proteins
  • Intercellular Adhesion Molecule-1